학술논문

NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases
Document Type
article
Source
Neurobiology of Aging. 36(3)
Subject
Biological Psychology
Biomedical and Clinical Sciences
Neurosciences
Psychology
Genetics
Genetic Testing
Human Genome
Neurodegenerative
Clinical Research
Rare Diseases
Alleles
Costs and Cost Analysis
Genetic Association Studies
Genetic Predisposition to Disease
Genetic Variation
Genotyping Techniques
Neurodegenerative Diseases
Oligonucleotide Array Sequence Analysis
Genotyping
Methods
Neurodegeneration
Parkinson's
Meta-analysis
Imputation
International Parkinson's Disease Genomics Consortium
Parkinson's Disease meta-analysis consortium
Clinical Sciences
Neurology & Neurosurgery
Biological psychology
Language
Abstract
Our objective was to design a genotyping platform that would allow rapid genetic characterization of samples in the context of genetic mutations and risk factors associated with common neurodegenerative diseases. The platform needed to be relatively affordable, rapid to deploy, and use a common and accessible technology. Central to this project, we wanted to make the content of the platform open to any investigator without restriction. In designing this array we prioritized a number of types of genetic variability for inclusion, such as known risk alleles, disease-causing mutations, putative risk alleles, and other functionally important variants. The array was primarily designed to allow rapid screening of samples for disease-causing mutations and large population studies of risk factors. Notably, an explicit aim was to make this array widely available to facilitate data sharing across and within diseases. The resulting array, NeuroX, is a remarkably cost and time effective solution for high-quality genotyping. NeuroX comprises a backbone of standard Illumina exome content of approximately 240,000 variants, and over 24,000 custom content variants focusing on neurologic diseases. Data are generated at approximately $50-$60 per sample using a 12-sample format chip and regular Infinium infrastructure; thus, genotyping is rapid and accessible to many investigators. Here, we describe the design of NeuroX, discuss the utility of NeuroX in the analyses of rare and common risk variants, and present quality control metrics and a brief primer for the analysis of NeuroX derived data.